Impact of Histological and Endoscopic Remissions on Clinical Recurrence and Recurrence-free Time in Ulcerative Colitis

Ponte, Ana; Pinho, Rolando; Fernandes, Sónia; Rodrigues, Adélia; Alberto, Luis; Silva, João Carlos; Silva, Joana; Rodrigues, Jaime; Sousa, Mafalda; Silva, Ana Paula; Proença, Luísa; Freitas, Teresa; Leite, Sónia; Carvalho, João

doi:10.1097/mib.0000000000001275

Cited by 59 publications

(40 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To clarify that point, there is a need for periodic measurements of PGE-MUM to be performed in the same patient and prospective follow-up be performed of patients with relapse. In recent years, treatments aimed at histological healing more advanced than mucosal healing have also been required, and reports of the comparison between histological healing and biomarkers have been found [22][23][24][25]. Further studies are needed to determine if PGE-MUM could be a biomarker to predict histologic healing.…”

Section: Discussionmentioning

confidence: 99%

Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis

et al. 2020

View full text Add to dashboard Cite

Background: Prostaglandin E-major urinary metabolite (PGE-MUM) may be a novel biomarker for evaluating disease activity in ulcerative colitis (UC). We compared its usefulness to that of the fecal immunochemical occult blood test (FIT). Methods: PGE-MUM and FIT measurements were performed of 92 urinary and fecal samples obtained from 60 patients with UC. Endoscopic activity was determined by Mayo endoscopic subscore (eMayo) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score. Results: PGE-MUM levels and FIT results showed a significant correlation with respect to eMayo (P < 0.001 and P < 0.001, respectively), and there was a significant difference in PGE-MUM values between the groups below eMayo1 and above eMayo2 (P = 0.012). Both biomarkers were significantly correlated with the UCEIS score (P < 0.001 and P < 0.001, respectively), and the PGE-MUM values were significantly different between groups below UCEIS1 and above UCEIS2 (P = 0.012). PGE-MUM and FIT were significantly correlated with eMayo in the group with a disease duration < 5 years (P = 0.041 and P < 0.001, respectively). Although PGE-MUM and eMayo differed significantly between groups over 5 years (P = 0.012), FIT was not correlated with eMayo (P = 0.101). Conclusions: PGE-MUM is useful as a biomarker as FIT for evaluating the endoscopic activity, particularly in longterm affected patients with UC.

show abstract

Section: Discussionmentioning

confidence: 99%

Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis

et al. 2020

View full text Add to dashboard Cite

show abstract

“… 55 Histologic remission has been shown to correlate with endoscopic improvement, higher rates of sustained steroid free remission, and decreased rates of clinical recurrence and hospitalizations. 56 , 57 , 58 , 59 …”

Section: Introductionmentioning

confidence: 99%

Assessing Severity of Disease in Patients with Ulcerative Colitis

Pabla

Schwartz

2020

Gastroenterology Clinics of North America

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a chronic disease that can present at various stages of disease activity and severity. Traditionally, severity scoring has focused on disease activity during a single moment with various tools, including patient-reported symptoms, as well as clinical, laboratory-based, endoscopic, histologic, and imaging variables. Optimal delivery of care depends on the accurate assessment of disease severity, which must take longitudinal variables into account. This article reviews the history of severity scoring in UC and provides a concise, clinically oriented approach to assessing disease severity.

show abstract

“…Confocal microscopy may give more solid information but is still not widely available 72 . Clearly, as a prognostic factor, histology is superior to clinical or endoscopy criteria 73 , 74 , but this does not necessarily imply that histology should guide treatment escalation. Even fecal markers like calprotectin were superior to the Mayo endoscopic score in a study from Japan 75 .…”

Section: Outlook: Selecting Patients Drugs and End Pointsmentioning

confidence: 99%

Recent advances and emerging therapies in the non-surgical management of ulcerative colitis

Wehkamp

Stange

2018

F1000Res

View full text Add to dashboard Cite

The so-called “biologicals” (monoclonal antibodies to various inflammatory targets like tumor necrosis factor or integrins) have revolutionized the treatment of inflammatory bowel diseases. In ulcerative colitis, they have an established role in inducing remission in steroid-refractory disease and, thereafter, maintaining remission with or without azathioprine. Nevertheless, their limitations are also obvious: lack of primary response or loss of response during maintenance as well as various, in part severe, side effects. The latter are less frequent in anti-integrin treatment, but efficacy, especially during induction, is delayed. New antibodies as well as small molecules have also demonstrated clinical efficacy and are soon to be licensed for ulcerative colitis. None of these novel drugs seems to be much more effective overall than the competition, but they provide new options in otherwise refractory patients. This increasing complexity requires new algorithms, but it is still premature to outline each drug’s role in future treatment paradigms.

show abstract

Impact of Histological and Endoscopic Remissions on Clinical Recurrence and Recurrence-free Time in Ulcerative Colitis

Abstract: The presence of histological activity represents an independent predictive factor of recurrence and time to recurrence, which was not verified with MSe 0 to 1.

Cited by 59 publications

References 21 publications

Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis

Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis

Assessing Severity of Disease in Patients with Ulcerative Colitis

Recent advances and emerging therapies in the non-surgical management of ulcerative colitis

Contact Info

Product

Resources

About